QT prolongation

[키워드] 1:1 2019-nCoV allergic Antipyretic Antiretroviral therapy Antiviral Arm as required assigned Breastfeeding Care categories cause clinical combination therapy compassionate use cough country COVID-19 COVID-19 infection criteria death defined described discharged disease dissemination drug Efficacy element eligibility criteria enrolled enrolment Etiquette exclusion criteria exploratory female Fever Frequency H1N1 hand hygiene Hydration Hydroxychloroquine ICU Patients inclusion criteria India Infection infection with SARS-CoV-2 investigator Laboratory Loading dose Lopinavir/ritonavir Lopinavir/Ritonavir combination mechanical ventilation medication Mortality non-ICU non-invasive ventilation Non-severe case Normalisation number nutrition objective off-label organ oxygen saturation paO2/fiO2 participant Participants Patient pharmacotherapy Placebo positive Precaution progression protocol QT prolongation randomisation randomised randomised controlled trial randomization Randomized controlled trial Randomly receipt recruitment regimen Registration registry replaced required Research respiratory rate ribavirin RT-PCR Safety Sample size SARS-CoV-2 RT-PCR screened secondary secure Serious Adverse Event Severe COVID-19 Infection Severe patient severity specimen Standard standard treatment status stratified study period Study protocol supplemental oxygen Support Suppressant surgical sustained symptomatic patient Tablet tested the patient therapeutic intervention therapy time time to defervescence treated Treatment treatment arm treatment group Trial upper respiratory tract Vasopressor Ventilation ventilator wear website
[DOI] 10.1186/s13063-020-04774-5 PMC 바로가기 [Article Type] Letter